Cinacalcet Mylan

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

cinakalcet hidroklorid

Available from:

Mylan Pharmaceuticals Limited

ATC code:

H05BX01

INN (International Name):

cinacalcet

Therapeutic group:

Homeostaza kalcija

Therapeutic area:

Hyperparathyroidism, Secondary; Hypercalcemia

Therapeutic indications:

Liječenje sekundarnog ť hiperparatireoidizma (HPT) u bolesnika u završnoj fazi bubrežne bolesti (ESRD) na dijalizu terapija održavanja. Цинакалцет Майлана može se koristiti kao dio zdravstvenog stanja, uključujući i fosfat i/ili vitamina D, steroli, po potrebi. Pad гиперкальциемии kod pacijenata s:parathyroid carcinomaprimary ТВД, za koje parathyroidectomywould biti drugačije na temelju razine kalcija u serumu (kao što je definirano u relevantnim smjernicama za liječenje), ali u kojima паратиреоидэктомия nije klinički ili je kontraindicirano.

Product summary:

Revision: 15

Authorization status:

odobren

Authorization date:

2015-11-19

Patient Information leaflet

                                38
B. UPUTA O LIJEKU
39
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA
_ _
CINACALCET MYLAN 30 MG FILMOM OBLOŽENE TABLETE
CINACALCET MYLAN 60 MG FILMOM OBLOŽENE TABLETE
CINACALCET MYLAN 90 MG FILMOM OBLOŽENE TABLETE
cinakalcet
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika, ljekarnika ili medicinsku
sestru. To uključuje i svaku moguću nuspojavu koja nije navedena u
ovoj uputi. Pogledajte dio
4.
_ _
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Cinacalcet Mylan i za što se koristi
2.
Što morate znati prije nego počnete uzimati Cinacalcet Mylan
3.
Kako uzimati Cinacalcet Mylan
4.
Moguće nuspojave
5.
Kako čuvati Cinacalcet Mylan
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE CINACALCET MYLAN I ZA ŠTO SE KORISTI
Cinacalcet Mylan sadrži djelatnu tvar cinakalcet koja djeluje
kontroliranjem razine paratiroidnog
hormona (PTH), kalcija i fosfora u Vašem tijelu. Koristi se u
liječenju tegoba povezanih s
paratireoidnim žlijezdama. Paratireoide su četiri male žlijezde na
vratu, pokraj štitnjače, koje
proizvode paratireoidni hormon (PTH).
Cinacalcet Mylan se koristi u odraslih:
•
za liječenje sekundarnog hiperparatireoidizma u bolesnika s ozbiljnom
bubrežnom bolesti koji
trebaju dijalizu da bi se krv očistila od štetnih produkata
•
da bi se smanjila visoka razina kalcija u krvi (hiperkalcemija) u
odraslih bolesnika s rakom
paratireoidnih žlijezda
•
da bi se smanjila visoka razina kalcija u krvi (hiperkalcemija) u
odraslih bolesnika s primarnim
hiperparatireoidizmom kod kojih odstranjenje paratireoidne žlijezde
nije moguće.
Cinacalcet Mylan se koristi u djece u dobi od 3 do manje
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Cinacalcet Mylan 30 mg filmom obložene tablete.
Cinacalcet Mylan 60 mg filmom obložene tablete.
Cinacalcet Mylan 90 mg filmom obložene tablete.
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Cinacalcet Mylan 30 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 30 mg cinakalceta (u obliku
cinakalcetklorida).
Cinacalcet Mylan 60 m
g filmom obložene tablete
Jedna filmom obložena tableta sadrži 60 mg cinakalceta (u obliku
cinakalcetklorida).
Cinacalcet Mylan 90 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 90 mg cinakalceta (u obliku
cinakalcetklorida).
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta.
Cinacalcet Mylan 30 mg filmom obložene tablete
Zelena filmom obložena, ovalna, bikonveksna tableta veličine 10,0 mm
x 6,4 mm s ukošenim rubom i
utisnutom oznakom “M” na jednoj strani tablete i “CI30” na
drugoj strani.
Cinacalcet Mylan 60 mg filmom obložene tablete
Zelena filmom obložena, ovalna, bikonveksna tableta veličine 12,5 mm
x 8,0 mm s ukošenim rubom i
utisnutom oznakom “M” na jednoj strani tablete i “CI60” na
drugoj strani.
Cinacalcet Mylan 90 mg filmom obložene tablete
Zelena filmom obložena, ovalna, bikonveksna tableta veličine 14,3 mm
x 9,0 mm s ukošenim rubom i
utisnutom oznakom “M” na jednoj strani tablete i “CI90” na
drugoj strani.
3
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Sekundarni hiperparatireoidizam
_Odrasli _
Liječenje sekundarnog hiperparatireoidizma (HPT) u odraslih bolesnika
sa završnim stadijem bolesti
bubrega na terapiji održavanja dijalizom.
_Pedijatrijska populacija _
Liječenje sekundarnog hiperparatireoidizma (HPT) u djece u dobi od 3
godine i starije sa završnim
stadijem bolesti bubrega na terapiji održavanja dijalizom u koje
sekundarni HPT nije adekvatno
kontroliran standardnim načinom liječenja (vidjeti dio 4.4).
Cinacalcet Mylan može biti dio terapijskog režima koji uključuje
tvari koje
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 20-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-11-2015
Patient Information leaflet Patient Information leaflet Spanish 20-03-2024
Public Assessment Report Public Assessment Report Spanish 27-11-2015
Patient Information leaflet Patient Information leaflet Czech 20-03-2024
Public Assessment Report Public Assessment Report Czech 27-11-2015
Patient Information leaflet Patient Information leaflet Danish 20-03-2024
Public Assessment Report Public Assessment Report Danish 27-11-2015
Patient Information leaflet Patient Information leaflet German 20-03-2024
Public Assessment Report Public Assessment Report German 27-11-2015
Patient Information leaflet Patient Information leaflet Estonian 20-03-2024
Public Assessment Report Public Assessment Report Estonian 27-11-2015
Patient Information leaflet Patient Information leaflet Greek 20-03-2024
Public Assessment Report Public Assessment Report Greek 27-11-2015
Patient Information leaflet Patient Information leaflet English 20-03-2024
Public Assessment Report Public Assessment Report English 27-11-2015
Patient Information leaflet Patient Information leaflet French 20-03-2024
Public Assessment Report Public Assessment Report French 27-11-2015
Patient Information leaflet Patient Information leaflet Italian 20-03-2024
Public Assessment Report Public Assessment Report Italian 27-11-2015
Patient Information leaflet Patient Information leaflet Latvian 20-03-2024
Public Assessment Report Public Assessment Report Latvian 27-11-2015
Patient Information leaflet Patient Information leaflet Lithuanian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 20-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-11-2015
Patient Information leaflet Patient Information leaflet Hungarian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 20-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-11-2015
Patient Information leaflet Patient Information leaflet Maltese 20-03-2024
Public Assessment Report Public Assessment Report Maltese 27-11-2015
Patient Information leaflet Patient Information leaflet Dutch 20-03-2024
Public Assessment Report Public Assessment Report Dutch 27-11-2015
Patient Information leaflet Patient Information leaflet Polish 20-03-2024
Public Assessment Report Public Assessment Report Polish 27-11-2015
Patient Information leaflet Patient Information leaflet Portuguese 20-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 20-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-11-2015
Patient Information leaflet Patient Information leaflet Romanian 20-03-2024
Public Assessment Report Public Assessment Report Romanian 27-11-2015
Patient Information leaflet Patient Information leaflet Slovak 20-03-2024
Public Assessment Report Public Assessment Report Slovak 27-11-2015
Patient Information leaflet Patient Information leaflet Slovenian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 20-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-11-2015
Patient Information leaflet Patient Information leaflet Finnish 20-03-2024
Public Assessment Report Public Assessment Report Finnish 27-11-2015
Patient Information leaflet Patient Information leaflet Swedish 20-03-2024
Public Assessment Report Public Assessment Report Swedish 27-11-2015
Patient Information leaflet Patient Information leaflet Norwegian 20-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 20-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 20-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 20-03-2024

Search alerts related to this product